According to a study published in the JAMA Neurology journal, people with Asian genes or those having low body mass index are at a higher risk of bleeding in the brain with a daily low dose of Aspirin. The risk is even higher in people who are not cardiac patients since Aspirin is a blood thinning agent.
On the contrary, the American Heart’s Association recommended that people above 70 years of age should consume a low dose of Aspirin to reduce the risk of cardiovascular disease. These recommendations paved a way for clinical trials to ensure the safety of administration of the drug which concluded with the potential risk of Aspirin and low usefulness in prolonging life expectancy.
These findings were a result of studying around 134,000 people who have no cardiac disease history. A group of people who took a low dose of Aspirin showed 0.63% chances of intracranial hemorrhage while the other group showed 0.46% chances with placebo.
Though, many caregivers prefer prescribing the drug, remaining healthcare professionals, especially cardiologist’s emphasis on improving lifestyle with a healthy diet, regular exercise and reduced fat and sugar content in the daily diet in order to reduce the risk associated with drug consumption and to maintain a healthy life of a patient.
Considering a constantly rising burden of cardiovascular disease coupled with aging demographics is an alarming situation for researchers to develop a solid solution to improve life expectancy with minimal health risk. Having said this, Aspirin is not the only area of study. Industry specialists are also studying other events closely associated with cardiac health. For example, a new study published in the BMJ states that the use of glucosamine in the treatment of pain associated with osteoarthritis is linked to the risk of developing a cardiovascular event in the patient.